Generex Biotechnology Corporatio (GNBT) 0.0217 $GNBT
Generex Announces Publication of AE37 Prostate Cancer Vaccine Study
PR Newswire - Wed Aug 06, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced publication of a follow-up study from a Phase I clinical trial of the immunotherapeutic agent AE37 in patients with prostate cancer. The study demonstrates an association between a specific immune response generated by AE37 and improved overall survival. The compound is being developed by Antigen Express, Inc. (www.antigenexpress.com), a wholly-owned subsidiary of Generex, for multiple cancer indications.
H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/748t6b/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Generex Biotechnology Corporation - Takeda Pharmaceutical Company Limited - Nanotherapeutics, Inc. - Novartis AG - CEL-SCI Corporation - OPKO Health, Inc. - Hemispherx Biopharma, Inc. - Medicago Inc. - BioDiem Ltd - NanoViricides, Inc. - Medigen Biotechnology Corporation - SIGA Technologies, Inc. - XOMA Corporation - Green Cross Corporation - Antigen Express, Inc. - Adimmune Corporation - TechnoVax, Inc. - Cocrystal Pharma, Inc. - PaxVax - Vivaldi Biosciences Inc. - Aprogen, Inc. - Akshaya Bio Inc. - Gemmus Pharma Inc. For more information visit http://www.researchandmarkets.com/research/74..._infection
Global Type 1 Diabetes Market 2014-2018 with Astrazeneca, Eli Lilly and Co, Novo Nordisk A/S & Sanofi-Aventis US Dominating
M2 - Mon Jun 23, 4:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5k8cfq/global_type_1) has announced the addition of the "Global Type 1 Diabetes Market 2014-2018 with Astrazeneca, Eli Lilly and Co, Novo Nordisk A/S & Sanofi-Aventis US Dominating" report to their offering. The Global Type 1 Diabetes Market will grow at a CAGR of 6.9% over the period 2013-2018. One of the main drivers in this market is the increase in the global type 1 diabetic population. The global type 1 diabetes population is increasing every year with an annual increase of 3 percent in children below 14 years of age. An increase in the type 1 diabetic population might increase the number of people opting for treatment. This will drive the sale and revenue of these drugs. The key vendors in the Global Type 1 Diabetes market are increasing their penetration in the emerging markets. Recent years have witnessed an increase in investment in manufacturing sites based in these countries with the intention to enhance the production of drugs such as insulin for local or global markets. For instance, the Frankfurt site is a key manufacturer for Sanofi diabetes products. However, Sanofi has invested in Russia for its Orel-based site to enable the production of insulin prefilled devices. For a similar category of products, Sanofi has also invested in a manufacturing site in Beijing to penetrate the market. Recently, Sanofi transferred the manufacturing technologies for Insuman insulin to Shantha Biotech in India (part of the Sanofi group). In 2009, Novo Nordisk completely transferred the production of NovoPen from Denmark to Tianjin. Also, in 2008, Novo Nordisk started the construction of an advanced insulin filling plant in Tianjin, which is expected to cater to the demand of the Chinese market for Penfill, the insulin based solution for injection in cartridges. Further, the report states that one of the major challenges is the side effects of current therapies for type 1 diabetes. A lack of effective treatment that can manage glucose levels without causing adverse effects considerably decreases effective disease management. Key Vendors - Astrazeneca plc - Eli Lilly and Co. - Novo Nordisk A/S - Sanofi-Aventis US LLC Other Prominent Vendors - Biodel Inc. - Diamyd Medical AB - DiaVacs Inc. - Generex Biotechnology Corp. - Lexicon Pharmaceuticals Inc. - Macrogenics Inc. - MannKind Corp. - Osiris Therapeutics Inc. - Tolerion Inc. - XOMA Corp. For more information visit http://www.researchandmarkets.com/research/5k...bal_type_1
Generex Announces Interview of Dr. Eric von Hofe, President of Antigen Express, Following Recent Keynote Presentation
PR Newswire - Tue Jun 17, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced the posting of an interview given by Dr. Eric von Hofe, Ph.D., President of the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), following his keynote presentation at the recent TIDES meeting. The 16th Annual TIDES Conference (www.IBCLifeSciences.com/Tides) was held in Providence, RI May 12 - 15, 2014. TIDES, Oligonucleotide and Peptide® Therapeutics from Research through Commercialization, is the premier meeting focused on the discovery and development of synthetic biologicals. The interview can be viewed online at:
Generex/Antigen Express Announce Interview of MD Anderson's Dr. Elizabeth Mittendorf, Principal Investigator on Company's AE37 Phase IIb Breast Cancer Efficacy Trial
PR Newswire - Thu Jun 12, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced an interview given by Dr. Elizabeth Mittendorf, M.D., Ph.D. Dr. Mittendorf is the Principal Investigator of the AE37 clinical trial to test the ability of the novel immunotherapeutic agent to prevent relapse in patients who have had HER2-expressing breast cancer, the largest Phase IIb peptide clinical trial conducted to date. AE37 is being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). The interview was conducted by Oncology TV at this year's Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago from May 30 to June 3. The interview can be viewed online at:
Generex Announces $2,075,000 Capital Investment
PR Newswire - Thu Mar 27, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that it entered into a securities purchase agreement with certain institutional investors on March 27, 2014. The investors have agreed to purchase in a private placement an aggregate of 2,075 shares of the Company's newly designated non-voting Series F 9% Convertible Preferred Stock ("convertible preferred stock"
and warrants to purchase up to an aggregate of 100% of the shares of its common stock issuable upon conversion of the convertible preferred stock ("warrants" at the closing. The convertible preferred stock and warrants will be sold in units, with each unit consisting of one share of convertible preferred stock and a warrant to purchase 100% of the shares of the Company's common stock issuable upon conversion of such shares of convertible preferred stock. Each unit will be sold at a negotiated price of $1,000 for an aggregate purchase price of $2,075,000. An aggregate of 138,333,333 shares of the Company's common stock will be issuable upon conversion of, or exercise of, the convertible preferred stock and warrants issued at the closing. In addition, until the one year anniversary of the date of closing, each investor may, in its sole determination, elect to purchase, severally and not jointly with the other investors, in one or more purchases, in the ratio of such investor's original subscription amount to the original aggregate subscription amount of all investors, additional units consisting of convertible preferred stock and warrants at a purchase price of $1,000 per unit with an aggregate subscription amount thereof of up to $2,075,000, which units will be identical to the units of convertible preferred stock and warrants issued in connection with the initial closing.
Generex/Antigen Express Announces Participation on Panel at Upcoming Cancer Immunotherapeutics Symposium
PR Newswire - Wed Mar 26, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that Dr. Eric von Hofe, Ph.D., the President of its wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be a member of a panel discussing immunotherapies for solid tumors at the Fourth Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference at the New York Academy of Medicine in New York City on March 27, 2014. This unique, single-day conference event unites founding visionary researchers, clinicians, business leaders, key investors, and other stakeholders to engage in discussions, exchange information, highlight opportunities, and showcase leading companies in the field of cancer immunotherapy.
Generex Biotechnology Corp. Granted Patents on New HPV and Influenza Vaccines
ACCESSWIRE - Wed Mar 12, 11:01AM CDT
Generex Biotechnology Corp. (OTCQB: GNBT) stock volume soared Mar. 11, with 9,325,106 shares changing hands, significantly higher than its three-month average volume of 7,012,285 shares.
Generex Biotechnology wins patents for vaccines targeting HPV induced cancers and influenza
M2 - Thu Mar 06, 6:05AM CST
Drug delivery company Generex Biotechnology (Other OTC:GNBT), based in Canada, reported on Wednesday the receipt of the US Patent Office's Notices of Allowance relating to applications for the use of therapeutic vaccines targeting cancers caused by human papilloma virus (HPV) as well as potentially pandemic strains of the influenza virus.
Generex Subsidiary Antigen Express Receives Patents for Vaccines Targeting HPV Induced Cancers and Influenza
PR Newswire - Wed Mar 05, 8:30AM CST
Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com) has received Notices of Allowance from the United States Patent Office relating to applications for the use of therapeutic vaccines targeting human papilloma virus (HPV) caused cancers as well as to potentially pandemic strains of influenza virus. The Company has previously received allowances of broad claims surrounding the use of its Ii-Key hybrid technology platform. Both applications relate to vaccines designed using this platform, which was also used to design its AE37 vaccine that is currently in a late Phase II trial to prevent relapse in patients who have had breast cancer.
Generex Announces Publication of Biomarker Studies Related to the Antigen Express Novel Immunotherapeutic AE37 in Prostate Cancer Patients
PR Newswire - Thu Feb 27, 8:30AM CST
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced publication of studies examining potential biomarkers associated with overall survival in prostate cancer patients treated with its immunotherapeutic agent AE37. The retrospective study examined data from 29 patients immunized as part of a Phase I study. The immunotherapeutic agent AE37 is being developed by Antigen Express, Inc. (www.antigenexpress.com), a wholly-owned subsidiary of Generex, for multiple cancer indications.
Generex/Antigen Express Interview on Clear Channel Business Talk Radio DFW 1190AM by Host Michael Yorba
Marketwire - Wed Feb 12, 9:26AM CST
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced that Dr. Eric von Hofe, PhD, President of the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be interviewed live today on Clear Channel's business talk radio show "The Traders Network" by host Michael Yorba:
Generex Provides Update on Antigen Express Phase II AE37 Breast Cancer Vaccine Trial
PR Newswire - Wed Feb 12, 8:30AM CST
Generex Biotechnology Corporation (www.generex.com) (GNBT) today announced that recent results from a Phase II study of a novel cancer vaccine designed to prevent relapse in patients who have had breast cancer corroborate prior results from an interim analysis conducted in October of 2011. The Company plans to disclose full results from the Phase II clinical trial at this year's American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago from May 30 to June 3, 2014. The ASCO Annual Meeting is the premier annual oncology symposium, bringing together more than 25,000 oncology professionals from a broad range of specialties. Two abstracts in respect of the results of the Phase II trial have been submitted to the ASCO Annual Meeting; per ASCO rules, the contents of those abstracts are embargoed pending the meeting.
Premature Babies Cost Employers $12.7 Billion Annually
PR Newswire - Fri Feb 07, 4:08PM CST
Preterm birth costs employers more than $12 billion in excess health care costs, according to new statistics from the March of Dimes. The high cost of preemies was spotlighted recently when AOL cited cuts to the company's 401(k) benefits on two "distressed" babies born to women working at the company.
Generex/Antigen Express "Stock News Now" Interview Available Online
PR Newswire - Tue Feb 04, 10:32AM CST
Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that an interview of Dr. Eric von Hofe, PhD, President of the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), conducted by Stock News Now at last month's J.P. Morgan Healthcare Conference in San Francisco, is now available online. The interview is in respect of the ongoing Phase II trial of the Antigen Express AE37 breast cancer vaccine.
borro® Reaches Milestone Of $100,000,000 Lent Against Luxury Assets And Rare Collectibles
PR Newswire - Wed Jan 29, 8:00AM CST
Leading personal asset lender borro® has reached the milestone of issuing over $100 million worth of loans. Offering a faster, less cumbersome approach to traditional bank lending, borro lends up to $1 million on personal assets including jewelry, watches, luxury cars, fine art and antiques, fine wine and more. With no invasive background checks, funds can be wired within 24-hours.
Viacom Forms Program Acquisitions Group
PR Newswire - Thu Jan 23, 8:38AM CST
Viacom Inc. (NASDAQ: VIAB, VIA) today announced the formation of a Program Acquisitions Group to coordinate the company's domestic program acquisition activity across its portfolio of domestic media networks, including BET, Centric, MTV, VH1, CMT, Comedy Central, Spike TV, TV Land, Nickelodeon and Nick at Nite.
Communal Clash Claims Two Lives in Enugu
by Christopher Isiguzo - All Africa Global Media - Fri Jan 17, 1:21AM CST
No fewer than two persons have been reported dead and eight others injured following a communal clash between two Enugu communities last Wednesday.
Generex Announces Completion of Enrollment of Antigen Express Phase II AE37 Breast Cancer Vaccine Trial
PR Newswire - Mon Jan 13, 8:30AM CST
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced completion of enrollment of the Antigen Express, Inc. (www.antigenexpress.com) AE37 breast cancer immunotherapy trial. The clinical trial is designed to assess the ability of AE37 to reduce the risk of relapse in patients who have had breast cancer. While a pre-planned primary efficacy analysis is underway, completion of enrollment sets the time-point for the end-of-trial analysis, scheduled to be conducted one year's time.
Florida Private Flood Bill Clears First Legislative Hurdle
Michael Buck - AMBest - Thu Jan 09, 3:09PM CST
The Florida Senate Committee on Banking and Insurance has unanimously approved a bill that lays out a framework for private companies to write primary flood insurance to potentially help deal with recent rate increases implemented by the National Flood Insurance Program.
Generex Announces Publication of AE37 Prostate Cancer Vaccine Study
PR Newswire - Wed Aug 06, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced publication of a follow-up study from a Phase I clinical trial of the immunotherapeutic agent AE37 in patients with prostate cancer. The study demonstrates an association between a specific immune response generated by AE37 and improved overall survival. The compound is being developed by Antigen Express, Inc. (www.antigenexpress.com), a wholly-owned subsidiary of Generex, for multiple cancer indications.
H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/748t6b/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Generex Biotechnology Corporation - Takeda Pharmaceutical Company Limited - Nanotherapeutics, Inc. - Novartis AG - CEL-SCI Corporation - OPKO Health, Inc. - Hemispherx Biopharma, Inc. - Medicago Inc. - BioDiem Ltd - NanoViricides, Inc. - Medigen Biotechnology Corporation - SIGA Technologies, Inc. - XOMA Corporation - Green Cross Corporation - Antigen Express, Inc. - Adimmune Corporation - TechnoVax, Inc. - Cocrystal Pharma, Inc. - PaxVax - Vivaldi Biosciences Inc. - Aprogen, Inc. - Akshaya Bio Inc. - Gemmus Pharma Inc. For more information visit http://www.researchandmarkets.com/research/74..._infection
Global Type 1 Diabetes Market 2014-2018 with Astrazeneca, Eli Lilly and Co, Novo Nordisk A/S & Sanofi-Aventis US Dominating
M2 - Mon Jun 23, 4:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5k8cfq/global_type_1) has announced the addition of the "Global Type 1 Diabetes Market 2014-2018 with Astrazeneca, Eli Lilly and Co, Novo Nordisk A/S & Sanofi-Aventis US Dominating" report to their offering. The Global Type 1 Diabetes Market will grow at a CAGR of 6.9% over the period 2013-2018. One of the main drivers in this market is the increase in the global type 1 diabetic population. The global type 1 diabetes population is increasing every year with an annual increase of 3 percent in children below 14 years of age. An increase in the type 1 diabetic population might increase the number of people opting for treatment. This will drive the sale and revenue of these drugs. The key vendors in the Global Type 1 Diabetes market are increasing their penetration in the emerging markets. Recent years have witnessed an increase in investment in manufacturing sites based in these countries with the intention to enhance the production of drugs such as insulin for local or global markets. For instance, the Frankfurt site is a key manufacturer for Sanofi diabetes products. However, Sanofi has invested in Russia for its Orel-based site to enable the production of insulin prefilled devices. For a similar category of products, Sanofi has also invested in a manufacturing site in Beijing to penetrate the market. Recently, Sanofi transferred the manufacturing technologies for Insuman insulin to Shantha Biotech in India (part of the Sanofi group). In 2009, Novo Nordisk completely transferred the production of NovoPen from Denmark to Tianjin. Also, in 2008, Novo Nordisk started the construction of an advanced insulin filling plant in Tianjin, which is expected to cater to the demand of the Chinese market for Penfill, the insulin based solution for injection in cartridges. Further, the report states that one of the major challenges is the side effects of current therapies for type 1 diabetes. A lack of effective treatment that can manage glucose levels without causing adverse effects considerably decreases effective disease management. Key Vendors - Astrazeneca plc - Eli Lilly and Co. - Novo Nordisk A/S - Sanofi-Aventis US LLC Other Prominent Vendors - Biodel Inc. - Diamyd Medical AB - DiaVacs Inc. - Generex Biotechnology Corp. - Lexicon Pharmaceuticals Inc. - Macrogenics Inc. - MannKind Corp. - Osiris Therapeutics Inc. - Tolerion Inc. - XOMA Corp. For more information visit http://www.researchandmarkets.com/research/5k...bal_type_1
Generex Announces Interview of Dr. Eric von Hofe, President of Antigen Express, Following Recent Keynote Presentation
PR Newswire - Tue Jun 17, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced the posting of an interview given by Dr. Eric von Hofe, Ph.D., President of the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), following his keynote presentation at the recent TIDES meeting. The 16th Annual TIDES Conference (www.IBCLifeSciences.com/Tides) was held in Providence, RI May 12 - 15, 2014. TIDES, Oligonucleotide and Peptide® Therapeutics from Research through Commercialization, is the premier meeting focused on the discovery and development of synthetic biologicals. The interview can be viewed online at:
Generex/Antigen Express Announce Interview of MD Anderson's Dr. Elizabeth Mittendorf, Principal Investigator on Company's AE37 Phase IIb Breast Cancer Efficacy Trial
PR Newswire - Thu Jun 12, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced an interview given by Dr. Elizabeth Mittendorf, M.D., Ph.D. Dr. Mittendorf is the Principal Investigator of the AE37 clinical trial to test the ability of the novel immunotherapeutic agent to prevent relapse in patients who have had HER2-expressing breast cancer, the largest Phase IIb peptide clinical trial conducted to date. AE37 is being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). The interview was conducted by Oncology TV at this year's Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago from May 30 to June 3. The interview can be viewed online at:
Generex Announces $2,075,000 Capital Investment
PR Newswire - Thu Mar 27, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that it entered into a securities purchase agreement with certain institutional investors on March 27, 2014. The investors have agreed to purchase in a private placement an aggregate of 2,075 shares of the Company's newly designated non-voting Series F 9% Convertible Preferred Stock ("convertible preferred stock"
and warrants to purchase up to an aggregate of 100% of the shares of its common stock issuable upon conversion of the convertible preferred stock ("warrants" at the closing. The convertible preferred stock and warrants will be sold in units, with each unit consisting of one share of convertible preferred stock and a warrant to purchase 100% of the shares of the Company's common stock issuable upon conversion of such shares of convertible preferred stock. Each unit will be sold at a negotiated price of $1,000 for an aggregate purchase price of $2,075,000. An aggregate of 138,333,333 shares of the Company's common stock will be issuable upon conversion of, or exercise of, the convertible preferred stock and warrants issued at the closing. In addition, until the one year anniversary of the date of closing, each investor may, in its sole determination, elect to purchase, severally and not jointly with the other investors, in one or more purchases, in the ratio of such investor's original subscription amount to the original aggregate subscription amount of all investors, additional units consisting of convertible preferred stock and warrants at a purchase price of $1,000 per unit with an aggregate subscription amount thereof of up to $2,075,000, which units will be identical to the units of convertible preferred stock and warrants issued in connection with the initial closing. Generex/Antigen Express Announces Participation on Panel at Upcoming Cancer Immunotherapeutics Symposium
PR Newswire - Wed Mar 26, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that Dr. Eric von Hofe, Ph.D., the President of its wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be a member of a panel discussing immunotherapies for solid tumors at the Fourth Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference at the New York Academy of Medicine in New York City on March 27, 2014. This unique, single-day conference event unites founding visionary researchers, clinicians, business leaders, key investors, and other stakeholders to engage in discussions, exchange information, highlight opportunities, and showcase leading companies in the field of cancer immunotherapy.
Generex Biotechnology Corp. Granted Patents on New HPV and Influenza Vaccines
ACCESSWIRE - Wed Mar 12, 11:01AM CDT
Generex Biotechnology Corp. (OTCQB: GNBT) stock volume soared Mar. 11, with 9,325,106 shares changing hands, significantly higher than its three-month average volume of 7,012,285 shares.
Generex Biotechnology wins patents for vaccines targeting HPV induced cancers and influenza
M2 - Thu Mar 06, 6:05AM CST
Drug delivery company Generex Biotechnology (Other OTC:GNBT), based in Canada, reported on Wednesday the receipt of the US Patent Office's Notices of Allowance relating to applications for the use of therapeutic vaccines targeting cancers caused by human papilloma virus (HPV) as well as potentially pandemic strains of the influenza virus.
Generex Subsidiary Antigen Express Receives Patents for Vaccines Targeting HPV Induced Cancers and Influenza
PR Newswire - Wed Mar 05, 8:30AM CST
Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com) has received Notices of Allowance from the United States Patent Office relating to applications for the use of therapeutic vaccines targeting human papilloma virus (HPV) caused cancers as well as to potentially pandemic strains of influenza virus. The Company has previously received allowances of broad claims surrounding the use of its Ii-Key hybrid technology platform. Both applications relate to vaccines designed using this platform, which was also used to design its AE37 vaccine that is currently in a late Phase II trial to prevent relapse in patients who have had breast cancer.
Generex Announces Publication of Biomarker Studies Related to the Antigen Express Novel Immunotherapeutic AE37 in Prostate Cancer Patients
PR Newswire - Thu Feb 27, 8:30AM CST
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced publication of studies examining potential biomarkers associated with overall survival in prostate cancer patients treated with its immunotherapeutic agent AE37. The retrospective study examined data from 29 patients immunized as part of a Phase I study. The immunotherapeutic agent AE37 is being developed by Antigen Express, Inc. (www.antigenexpress.com), a wholly-owned subsidiary of Generex, for multiple cancer indications.
Generex/Antigen Express Interview on Clear Channel Business Talk Radio DFW 1190AM by Host Michael Yorba
Marketwire - Wed Feb 12, 9:26AM CST
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced that Dr. Eric von Hofe, PhD, President of the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be interviewed live today on Clear Channel's business talk radio show "The Traders Network" by host Michael Yorba:
Generex Provides Update on Antigen Express Phase II AE37 Breast Cancer Vaccine Trial
PR Newswire - Wed Feb 12, 8:30AM CST
Generex Biotechnology Corporation (www.generex.com) (GNBT) today announced that recent results from a Phase II study of a novel cancer vaccine designed to prevent relapse in patients who have had breast cancer corroborate prior results from an interim analysis conducted in October of 2011. The Company plans to disclose full results from the Phase II clinical trial at this year's American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago from May 30 to June 3, 2014. The ASCO Annual Meeting is the premier annual oncology symposium, bringing together more than 25,000 oncology professionals from a broad range of specialties. Two abstracts in respect of the results of the Phase II trial have been submitted to the ASCO Annual Meeting; per ASCO rules, the contents of those abstracts are embargoed pending the meeting.
Premature Babies Cost Employers $12.7 Billion Annually
PR Newswire - Fri Feb 07, 4:08PM CST
Preterm birth costs employers more than $12 billion in excess health care costs, according to new statistics from the March of Dimes. The high cost of preemies was spotlighted recently when AOL cited cuts to the company's 401(k) benefits on two "distressed" babies born to women working at the company.
Generex/Antigen Express "Stock News Now" Interview Available Online
PR Newswire - Tue Feb 04, 10:32AM CST
Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that an interview of Dr. Eric von Hofe, PhD, President of the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), conducted by Stock News Now at last month's J.P. Morgan Healthcare Conference in San Francisco, is now available online. The interview is in respect of the ongoing Phase II trial of the Antigen Express AE37 breast cancer vaccine.
borro® Reaches Milestone Of $100,000,000 Lent Against Luxury Assets And Rare Collectibles
PR Newswire - Wed Jan 29, 8:00AM CST
Leading personal asset lender borro® has reached the milestone of issuing over $100 million worth of loans. Offering a faster, less cumbersome approach to traditional bank lending, borro lends up to $1 million on personal assets including jewelry, watches, luxury cars, fine art and antiques, fine wine and more. With no invasive background checks, funds can be wired within 24-hours.
Viacom Forms Program Acquisitions Group
PR Newswire - Thu Jan 23, 8:38AM CST
Viacom Inc. (NASDAQ: VIAB, VIA) today announced the formation of a Program Acquisitions Group to coordinate the company's domestic program acquisition activity across its portfolio of domestic media networks, including BET, Centric, MTV, VH1, CMT, Comedy Central, Spike TV, TV Land, Nickelodeon and Nick at Nite.
Communal Clash Claims Two Lives in Enugu
by Christopher Isiguzo - All Africa Global Media - Fri Jan 17, 1:21AM CST
No fewer than two persons have been reported dead and eight others injured following a communal clash between two Enugu communities last Wednesday.
Generex Announces Completion of Enrollment of Antigen Express Phase II AE37 Breast Cancer Vaccine Trial
PR Newswire - Mon Jan 13, 8:30AM CST
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced completion of enrollment of the Antigen Express, Inc. (www.antigenexpress.com) AE37 breast cancer immunotherapy trial. The clinical trial is designed to assess the ability of AE37 to reduce the risk of relapse in patients who have had breast cancer. While a pre-planned primary efficacy analysis is underway, completion of enrollment sets the time-point for the end-of-trial analysis, scheduled to be conducted one year's time.
Florida Private Flood Bill Clears First Legislative Hurdle
Michael Buck - AMBest - Thu Jan 09, 3:09PM CST
The Florida Senate Committee on Banking and Insurance has unanimously approved a bill that lays out a framework for private companies to write primary flood insurance to potentially help deal with recent rate increases implemented by the National Flood Insurance Program.
